tag:blogger.com,1999:blog-8096837022525265562024-03-18T03:33:20.452-04:00Medicine for residentsSamsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.comBlogger101125tag:blogger.com,1999:blog-809683702252526556.post-72669428726166578982018-07-15T23:03:00.000-04:002018-07-15T23:03:37.679-04:00hyperparathyroidism treatment<div dir="ltr" style="text-align: left;" trbidi="on">
<span class="Apple-style-span" style="color: #474a51; font-family: "arial" , "helvetica" , sans-serif; font-size: 16px;"></span><br />
<h5 style="color: #434241; font: bold 0.8em/0.5em Arial, Helvetica, sans-serif; margin: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 1em;">
<a href="http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/hypercalcemia/">http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/hypercalcemia/</a></h5>
<h5 style="color: #434241; font: bold 0.8em/0.5em Arial, Helvetica, sans-serif; margin: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 1em;">
<br />
</h5>
<h5 style="color: #434241; font: bold 0.8em/0.5em Arial, Helvetica, sans-serif; margin: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 1em;">
Indications for Treatment.</h5>
<div style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em; margin-top: 0.75em;">
Removal of the abnormal and hyperfunctioning parathyroid tissue results in a long-term cure of HPT in 96% of patients and significant improvement in associated symptoms. The following criteria were proposed as indications for parathyroidectomy based on a National Institutes of Health–sponsored panel and endocrine specialty societies:<sup> <a href="http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/hypercalcemia/#bib7" style="color: #365ea4; text-decoration: underline;">7</a></sup></div>
<ol style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em;">
<li>Serum Ca level more than 1 mg/dL above the upper limit of normal</li>
<li>Marked hypercalciuria higher than 400 mg/day</li>
<li>Creatinine clearance reduced more than 30% compared with age-matched controls</li>
<li>Reduction in bone mineral density of the femoral neck, lumbar spine, or distal radius of more than 2.5 standard deviations below peak bone mass (T score lower than -2.5)</li>
<li>Age younger than 50 years</li>
<li>Patients for whom medical surveillance is not desirable or possible</li>
<li>Presence of any complications (e.g., nephrolithiasis, overt bone disease)</li>
<li>An episode of hypercalcemic crisis</li>
</ol>
<div style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em; margin-top: 0.75em;">
However, because no effective medical therapy for HPT exists, all patients with HPT who are otherwise healthy for surgery should be referred for surgical treatment.</div>
<div style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em; margin-top: 0.75em;">
</div>
<h5 style="color: #434241; font: bold 0.8em Arial, Helvetica, sans-serif; margin: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 1em;">
Surgical Treatment.</h5>
<div style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em; margin-top: 0.75em;">
Parathyroid surgery remains the single most effective treatment option in HPT and requires removal of all abnormal parathyroid tissue. Traditionally, in the vast majority of U.S. practices, this has meant bilateral exploration of the neck to identify all (typically four) parathyroids, assess which ones are abnormal, and remove only the abnormal glands. The setting of multiglandular hyperplasia requires subtotal parathyroidectomy or total parathyroidectomy, with reimplantation of parathyroid tissue into the sternocleidomastoid or forearm muscles. The parathyroids may then also be cryopreserved as a safeguard against future hypocalcemia, in which case the patient may undergo autotransplantation of autogenous, stored parathyroid tissue. In experienced hands, this approach has an exceptional rate of successful long-term cure of HPT (more than 96%) and a low rate of surgical complications (hypocalcemia less than 1%, recurrent laryngeal nerve injury 2% to 5%, neck hematoma or infection less than 1%).<sup> <a href="http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/hypercalcemia/#bib8" style="color: #365ea4; text-decoration: underline;">8</a></sup></div>
<div style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em; margin-top: 0.75em;">
In recent years, parathyroid procedures have been developed using smaller incisions under sedation and local anesthesia, and with the opportunity for outpatient surgery. Minimally invasive parathyroid surgery has become more frequently requested by patients and primary care physicians alike, even though it does not represent a uniform set of techniques. Depending on regional practices, minimally invasive parathyroid surgery can include laparoscopic, radio-guided or, most frequently, only unilateral neck surgery. The success of these approaches in curing HPT and minimizing complications is relatively unknown because clinical follow-up periods are still short. Minimally invasive parathyroid surgery is appropriate only for patients who have a single, clearly defined parathyroid abnormality on ultrasound, sestamibi scan, or both and when parathyroid hormone levels can be monitored intraoperatively. Bilateral neck exploration is mandatory in all other cases and for patients with familial or genetic syndromes.</div>
<h5 style="color: #434241; font: bold 0.8em Arial, Helvetica, sans-serif; margin: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 1em;">
Medical Treatment.</h5>
<div style="font-family: Arial, Helvetica, sans-serif; font-size: 0.75em; line-height: 1.4em; margin-top: 0.75em;">
Patients who are not treated surgically should be managed to ensure good hydration and to avoid thiazide diuretics. Ambulation should be encouraged. Calcium intake should be average, because excessive intake may aggravate hypercalcemia, especially in patients with high calcitriol levels, whereas low calcium intake may stimulate PTH secretion. Bisphosphonates may be used to lower the serum calcium level in patients with symptomatic hypercalcemia (see later, “Treatment of Hypocalcemia”), although they are usually not effective.</div>
</div>
Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com30tag:blogger.com,1999:blog-809683702252526556.post-45052297744492631582011-08-17T23:53:00.000-04:002011-08-17T23:53:36.754-04:00beta blockers in COPD<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">It has been a looong gap ....moving and starting a fellowship in a new place is a little tough. Anyway I have settled down in my new place now. </span><div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Let me start with a short blog..regarding a discussion between a pulmonary fellow and the primary team that I happened to hear while doing my usual hyponatremia consult!</span></div><div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Traditionally betablockers were not used in patients with COPD or asthma due to bronchospam. But using a cardioselective agent may not afect the airways.But a recent <a href="http://www.bmj.com/content/342/bmj.d2549.full">retrospective study in bmj</a> went a step ahead and showed that it may be even beneficial in patients with COPD. </span></div><div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Of nearly 6000 patients with different stages of COPD ,they found that <span class="Apple-style-span" style="color: #333333;"><span class="Apple-style-span" style="line-height: 16px;">there was a 22% reduction in all cause mortality from beta blockers. The benifit was shown across all stages of COPD. With regards to lung function, they did not affect FEV1/FVC. also betablockers seemed to have additive benifits on hospital admissions. This benifit was seen independent of presence of cardiovascular disease.</span></span></span></div><div><span class="Apple-style-span" style="color: #333333; font-family: arial, sans-serif;"><span class="Apple-style-span" style="font-size: 12px; line-height: 16px;"><br />
</span></span></div><div><span class="Apple-style-span" style="color: #333333; font-family: arial, sans-serif;"><span class="Apple-style-span" style="font-size: 12px; line-height: 16px;"><img alt="Figure" src="http://www.bmj.com/content/342/bmj.d2549/F1.medium.gif" /></span></span></div><div><span class="Apple-style-span" style="color: #333333; font-family: arial, sans-serif;"><span class="Apple-style-span" style="font-size: 12px; line-height: 16px;"><br />
</span></span></div><div><span class="Apple-style-span" style="color: #333333; font-family: arial, sans-serif;"><span class="Apple-style-span" style="font-size: 12px; line-height: 16px;"><br />
</span></span></div><div><span class="Apple-style-span" style="color: #333333;"><span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">A somewhat related study published by one of my senior resident(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981154/">Int J Chron Obst Pulm Disease 2010</a></span></span></span><span class="Apple-style-span" style="color: #333333;"><span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">) showed that patients with COPD may have unrecognised myocardial injury. May be betablockers help with this and this is what we are seeing here. </span></span></span></div><div><span class="Apple-style-span" style="color: #333333; font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 16px;">Time to change practice!!</span></span></div></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com40tag:blogger.com,1999:blog-809683702252526556.post-21224020107729037332011-05-25T00:23:00.003-04:002011-05-25T00:25:26.378-04:00Osteoporosis --- Screening & Treatment<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Osteoporosis is very much underdiagnosed, and under treated! I recently did my practice based learning exercise on Osteoporosis, and sadly...I havent screened or treated many of my patients!!</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">So lets see who needs to be screened, and who needs treatement...</span><br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgaPaPvx__HLv5XbnljyAYOo6eLFG9BnVZ6TttpWlr8lFt5mk4_d5d12M3ffPzPXHqEItdyG8_U1iAuB05sOn7PKb9DPSuoptqFmgCHFiA1K5Ujr3-ERe-AvsQrY0mSvK7may8mcLkkwno/s1600/osteoporosis.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgaPaPvx__HLv5XbnljyAYOo6eLFG9BnVZ6TttpWlr8lFt5mk4_d5d12M3ffPzPXHqEItdyG8_U1iAuB05sOn7PKb9DPSuoptqFmgCHFiA1K5Ujr3-ERe-AvsQrY0mSvK7may8mcLkkwno/s1600/osteoporosis.png" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">DEXA Scan and scoring - Screening /diagnosing is done by DEXA scan . The 2 preferred sites of scanning are lumbar spine and proximal femur,as these places show the earliest sign of osteoporosis. So next time when you see a score based on a heel DEXA ....it is not a complete test! A T-score( representing the number of standard deviations between the pts bone mineral density and a healthy young adult of same sex) less than -2.5 is called osteoporosis, and a score between -1 to -2.5 is osteopenia. </span><br />
<span class="Apple-style-span" style="line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="color: #333333;">The Z-score is used to classify the type of osteoporosis. A score below 1.5 indicates </span><b style="color: #333333;">primary osteoporosis</b><span class="Apple-style-span" style="color: #333333;">, which is age related. A score of 1.5 and higher indicates </span><b style="color: #333333;">secondary osteoporosis</b><span class="Apple-style-span" style="color: #333333;">, which is associated with calcitonin imbalance, malabsorption conditions ,</span><span class="Apple-style-span" style="color: black;">alcohol abuse, smoking</span><span class="Apple-style-span" style="color: #333333;">, medications etc.</span></span></span><br />
<span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>Screening</b> - The following are the group of people who need DEXA for screening</span></span><br />
<br />
<ul style="text-align: left;"><li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">women 65yrs and older,</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> men 70 yrs and older,</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Loss of height of >2 inches (before DEXA...do a vertebral fracture survey...and if +ve, treat as osteoporosis)</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">postmenopausal women or, men >50 yrs with risk for fracture including h/o hip fracture in parents, current smoker or alcoholic, rheumatoid arthritis.</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">chronic glucocorticoid therapy(5mg/d or more of prednisone for >3 mon)</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">pts with medical diseaseassociated with decreased BMD(eg. renal disease, hyperthyroisim, cushings etc)</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">pts on medications that might reduce BMD ( anticonvulsants, PPI,Cyclosporine, SSRI etc</span></span></li>
</ul><div><span class="Apple-style-span" style="color: #333333; font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 19px; word-spacing: 1px;"><b>Who needs treatment</b> - </span></span></div><div><ul style="text-align: left;"><li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Anyone who has sustained a fragility fracture of hip or spine</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Those who have a T-score > or = 2.5, after evaluation for secondary causes of osteoporosis.</span></span></li>
<li><span class="Apple-style-span" style="color: #333333; line-height: 19px; word-spacing: 1px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Those who have osteopenia(a score between -1 & -2.5) if their 10 year probablity of osteoporotic fracture is >20% or 10 yr risk of hip fracture >3%. ( the risk called <a href="http://www.sheffield.ac.uk/FRAX/tool.jsp">FRAX</a> ..can be calculated online)</span></span></li>
</ul><div><span class="Apple-style-span" style="color: #333333; font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 19px; word-spacing: 1px;">Treatment - Bisphosphonates are the mainstay of treatment. A quick note is...of all the treatment modalities, Ibandronate, Calcitonin, Raloxifene, and Teriparatide are the ones which have not shown any hip fracture reduction. All of them reduce the incidence of spine fracture though.</span></span></div></div></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com23tag:blogger.com,1999:blog-809683702252526556.post-9775222612552535962011-05-17T22:19:00.002-04:002011-05-18T00:08:53.330-04:00Pre exposure prophylaxis for HIV<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">A homosexual male who is an iv drug abuser walks into the office...asking ways to help him prevent contacting HIV..with his high risk behaviour!! Apart from advising on safe sex and risks of sharing needles(which are most important..and at the same time cannot be relied at all times due to non adherence)....do we have any medications to offer him??</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<a href="http://t2.gstatic.com/images?q=tbn:ANd9GcQ9mWqbEl_jxCGM769yl3RPPbGdrQQggS5SuAZ06p7aMr-DKS16Cg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="200" src="http://t2.gstatic.com/images?q=tbn:ANd9GcQ9mWqbEl_jxCGM769yl3RPPbGdrQQggS5SuAZ06p7aMr-DKS16Cg" width="199" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Lets look at the <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1011205#t=article">iPREX study</a> published in NEJM Dec 2010. This was a placebo-controlled, double-blind, randomized trial involving 2499 subjects(men who have sex with men) to see if a combination of Emtricitabine-Tenofivir(FTC-TDF) once daily reduced the incidence of HIV over a f/u period of 1.2 years. Of the 100 incident HIV infections during the study period, 64 occurred in the placebo group and 36 in the FTC–TDF group, with an efficacy of 44% and a 95% CI of 15 to 63. An important finding to note is that, in the FTC–TDF group, the study drug was pharmacologically detected in 51% of subjects who remained free of HIV infection but in only 9% of those who became infected. So exposure to FTC–TDF was associated with a reduction in HIV acquisition. Main issues in putting this into practice has a few concerns. Few of them are drug adherence(very poor in the study), long term outcome, side effects(quite a few in the study drug group had renal impairement which rverted to normal on discontinuation of drug!). All these issues have been nicely discussed in the letter following the study( <a href="http://www.nejm.org/doi/full/10.1056/NEJMe1012929">another arrow in the Quiver.NEJM Dec 2010</a>)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Now the trial has been extended to look for long term outcomes and ways to improve adherence. results are expected by 2013.(<a href="http://sciencespeaksblog.org/2011/02/08/extended-iprex-study-looks-at-long-term-safety-behavior-change-and-medication-adherence/">HIV & TB News</a>)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">An earlier study , <a href="http://www.ncbi.nlm.nih.gov/pubmed/20643915">CAPRISA 004</a> in which a<span class="Apple-style-span" style="line-height: 18px;"> total of 889 sexually active, HIV-uninfected women (age range, 18–40) received either 1% tenofovir gel or placebo gel, with instructions to administer the gel intravaginally within 12 hours before sex and also within 12 hours after sex. </span><span class="Apple-style-span" style="line-height: 18px;">Mean follow-up was 18 months.The</span><span class="Apple-style-span" style="line-height: 18px;"> incidence of HIV was 5.6 /100 person-years in the tenofovir group versus 9.1 /100 person-years in the placebo group, for an incidence rate ratio (IRR) of 0.61 (95% CI, 0.40–0.94; <i>P</i>=0.017). Shows promise for pre exposure prophylaxis.</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">In this context ...</span>FEM-PrEP trial has to be mentioned. This study evaluated if oral daily FTC-TDF prevented HIV in a group of high risk women. The study was stopped last month after an interim analysis didnt find any benefit compared to placebo.(<a href="http://www.avac.org/ht/display/ReleaseDetails/i/33409/pid/212">AVAC April 2011</a>). Full analysis of trial should be available shortly.(may be related to adherence issues!!)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><a href="http://www.mtnstopshiv.org/node/3198">VOICE trial </a>- Vaginal and Oral Interventions to Control the Epidemic .........is an ongoing study on high risk women comparing FTC-TDF, tenofovir tablet alone , or tenofovir gel. This study might shed light into ..which of these will be more effective. By this time we will also have the long term safety and compliance outcomes on the i-PREX study.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">May be 2013 might be a year the world would see a... 'HIV prevention pill' !!!</span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com21tag:blogger.com,1999:blog-809683702252526556.post-60464087558607896162011-05-13T17:00:00.002-04:002011-05-13T17:08:37.189-04:00The "aura" of migraine<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Migraine can be with or without aura. What exactly comprises this aura. The prodromal and associated migraine symptoms may me mistaken as aura. Lets see what comprises the so called aura. It is the migraine with aura that is related to an increased incidence of ischemic stroke, and is a contraindication for taking oral contracptives!(as risk of stroke increases 4 fold in this population)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; font-size: 13px;"></span><br />
<div style="margin-bottom: 12px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 3px; padding-right: 0px; padding-top: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">The migraine aura is a complex of neurologic symptoms that may precede or accompany the headache phase or may occur in isolation. It usually develops over 5-20 minutes and lasts less than 60 minutes. The aura can be visual, sensory, motor, or any combination of these.</span></div><div style="margin-bottom: 12px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 3px; padding-right: 0px; padding-top: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><object class="BLOGGER-youtube-video" classid="clsid:D27CDB6E-AE6D-11cf-96B8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0" data-thumbnail-src="http://1.gvt0.com/vi/gV_37cao38U/0.jpg" height="266" width="320"><param name="movie" value="http://www.youtube.com/v/gV_37cao38U&fs=1&source=uds" /><param name="bgcolor" value="#FFFFFF" /><embed width="320" height="266" src="http://www.youtube.com/v/gV_37cao38U&fs=1&source=uds" type="application/x-shockwave-flash"></embed></object>Auras most commonly consist of visual symptoms, which may be negative or positive. Negative symptoms include negative scotoma, homonymous hemianopic or quadrantic field defects, central scotomas, tunnel vision, altitudinal visual defects, or even complete blindness.The most common positive visual phenomenon is the scintillating scotoma. This consists of an arc or band of absent vision with a shimmering or glittering zigzag border. It is often combined with photopsias or visual hallucinations, which may take various shapes.Scintillating scotoma is a highly characteristic syndrome that always occurs prior to the headache phase of an attack and is pathognomonic of a classic migraine.Other positive visual phenomena include photopsia (uniform flashes of light) or simple forms of visual hallucinations. Heat waves, fractured vision, macropsia, micropsia, and achromatopsia may also occur.</span></div><div style="margin-bottom: 12px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 3px; padding-right: 0px; padding-top: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Paresthesias, occurring in 40% of cases, constitute the next most common aura; they are often cheiro-oral with numbness starting in the hand, migrating to the arm, and then jumping to involve the face, lips, and tongue. As with visual auras, positive symptoms typically are followed by negative symptoms; paresthesias may be followed by numbness. Sensory aura rarely occurs in isolation and usually follows visual aura. </span></div><div style="margin-bottom: 12px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 3px; padding-right: 0px; padding-top: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Motor symptoms may occur in 18% of patients and usually are associated with sensory symptoms. Motor symptoms often are described as a sense of heaviness of the limbs before a headache but without any true weakness.Speech and language disturbances have been reported in 17-20% of patients. These disturbances are commonly associated with upper extremity heaviness or weakness.</span></div><div style="margin-bottom: 12px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 3px; padding-right: 0px; padding-top: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">The migrainous aura generally resolves within a few minutes and then is followed by a latent period before the onset of headache.When an aura is not followed by a headache, it is called a migraine equivalent or acephalic migraine. This is reported most commonly in patients older than 40 years who have a history of recurrent headache.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Again....all this means...that we need a more detailed history from these patients to elicit these findings!!</span></div></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com24tag:blogger.com,1999:blog-809683702252526556.post-50384624359739686292011-05-09T01:10:00.000-04:002011-05-09T01:10:41.190-04:00Headache - - Trigeminal autonomic cephalalgias!!<div dir="ltr" style="text-align: left;" trbidi="on">Lets talk some neurology, as this month Iam doing neurology! When discussing headache, we came across this entity called 'Trigeminal autonomic cephalgias' -- a group of headache disorders with pain referred to the 1st branch of trigeminal nerve associated with cranial autonomic symptoms including lacrimation, injection of the eye and rhinorrhea. They all share the same pathophysiologic etiology....which is largely unknown!!! But there is some eveidence of posterioir hypothalamus in modulating this craniofacial pain, as found out by functional imaging of brain (<a href="http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(09)70133-4/fulltext">Lancet 2009</a>)There are 3 types, and they vary in their frequency and duration..<br />
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj4G7BqZ4Q5P_xRHE4l_027Eiic7aTPQ1nJZf_zxryJqFLkFek6sE-O8P4JNRzMNgpRnE1dMs83zFOgK3s1jpmRLq78dnEYqUIsjBKgqRQgXPbIwNLRjbOh5vB0e0_w7WbNWwg6i70VSSI/s1600/TAC.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj4G7BqZ4Q5P_xRHE4l_027Eiic7aTPQ1nJZf_zxryJqFLkFek6sE-O8P4JNRzMNgpRnE1dMs83zFOgK3s1jpmRLq78dnEYqUIsjBKgqRQgXPbIwNLRjbOh5vB0e0_w7WbNWwg6i70VSSI/s1600/TAC.png" /></a></div><br />
1.Cluster headache - 1 to 8 attacks per day with the mean duration of each attack being 60 min.<br />
2.Paroxsmal hemicrania - 11 to 15 attack per day with a mean duration 15 min/attack<br />
3.SUNCT syndrome (Short lasting Unilateral neuralgiform headache with Conjuctival injection and Tearing) - roughly 20 atatcks per day with a mean duration of 30 sec to 2 min/attack.<br />
<br />
Well this sounds like, that someone just wanted to classify them to make it difficult for others to remember. But it turns out that differentiating these 3 on the basis of duration is important as treatment options are different!<br />
*Indomethacin works well in paroxysmal hemicrania(PH) and SUNCT, whereas it does not help patients with Cluster headache(CH).<br />
*Sumatriptan and Oxygen can help CH, whereas they dont help PH & SUNCT<br />
*For prophylactic treatment for CH, PH, & SUNCT...the drug of choice are Verapamil, Indomethacin & Lamotrigine respectively.<br />
Have a look at this article from UK which explains in detail about these 3 headaches. Especially peek at the table on page 118.(<a href="http://www.ncbi.nlm.nih.gov/pubmed/17355838">Current Neuro & neurosci report 2007</a>). Looks like ..we may need to be more specific with timing and duration of headaches, as we do for evaluation of chest pains!</div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com7tag:blogger.com,1999:blog-809683702252526556.post-68054853184431935722011-05-01T21:34:00.000-04:002011-05-01T21:34:49.142-04:00Elevated pulse pressure and white coat effect<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Can we differentiate white coat effect from true hypertension in the office?</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Difficult(we usually need either a 24 hr ambulatory BP monitoring or frequent home BP measurements.....both of which are cumbersome, and cant be done regularly).....but may be possible.....says Dr.Ahn from Korea, when he presented his study in the <a href="http://www.theheart.org/article/1210693.do">American College of Cardiology Scientific sessions </a>earlier this month. Lets see what they found out..</span><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://t2.gstatic.com/images?q=tbn:ANd9GcRYfaf-mcFIwhyfMeotCmGwkGpTUsAODwUxevhdGNdozHAMPlh7" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://t2.gstatic.com/images?q=tbn:ANd9GcRYfaf-mcFIwhyfMeotCmGwkGpTUsAODwUxevhdGNdozHAMPlh7" /></a></div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">They took 1087 outpatients with chronically treated hypertension, and checked home BP twice daily for 2 week, and then checked it in the office. White coat effect <span class="Apple-style-span" style="line-height: 16px;">was defined as a difference between the physician's BP and the home BP of above 20 mm Hg systolic or 10 mm Hg diastolic BP. </span><span class="Apple-style-span" style="line-height: 16px;">White-coat hypertension was found in 31% of patients. </span><span class="Apple-style-span" style="line-height: 16px;">Pulse pressure of 60 mm Hg and above positively correlated with WCE by multivariate analysis. So the author concluded that...</span><span class="Apple-style-span" style="line-height: 16px;"> if a patient has an elevated BP reading in the clinic along with elevated pulse pressure, we can consider WCE before recommending antihypertensive agents. </span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Some other interesting associations from the study : </span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">1. White-coat hypertension was not associated with age or gender in the study, </span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">2. Those with a family history of premature coronary disease were more likely to display WCE.</span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">3. Those with diabetes or organ damage including the heart, as well as smokers, were less likely to show WCE.</span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 16px;">The positive relationship with family history might be the result from the effects of anxiety and emotional stress, and t</span><span class="Apple-style-span" style="line-height: 16px;">he negative relationship with diabetes or smoking means that the WCE was relatively benign in these patients. Also pts with diabetes and organ damage may not be able to mount a stress response due to autonomic imbalance, LV dysfuction etc.</span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 16px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Is this important? Well.... it is...as we all know that white coat hypertension is a predecessor for chronic hypertension, as based on the findings from Italy(<a href="http://hyper.ahajournals.org/cgi/reprint/54/2/226">Hypertension 2009</a>) ...in which thy followed nearly 1400 pts with white coat or masked hypertension , and found that 40% of patients with white coat effect progressed to develop Hypertension over a period of 10 years. So..YES...WHITE COAT HYPERTENSION needs to be identified and monitored closely. We usually dont treat WCH due to risk of hypotension...but they need to be monitored closely for development of hypertension. </span></span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com19tag:blogger.com,1999:blog-809683702252526556.post-77836014973994301062011-04-25T19:22:00.000-04:002011-04-25T19:22:22.003-04:00Norepinephrine or Dopamine?<div dir="ltr" style="text-align: left;" trbidi="on">It looks like...we may have a winner. Yes<br />
Im talking about the use of vasopressors in the setting of septic shock. There have been a few clinical trials done to see if one vasopressor is better than the other in terms of mortality from septic shock. (the latest one was from <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa0907118#t=article">SOAP 2 trial from NEJM 2010</a>)We didnt have a clear result so far.<br />
<br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://t3.gstatic.com/images?q=tbn:ANd9GcTtlYEg2EmlgvkqAwtfvCBrfaGSek1UcXELcwAyaMlntYNF9HbIqg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="190" src="http://t3.gstatic.com/images?q=tbn:ANd9GcTtlYEg2EmlgvkqAwtfvCBrfaGSek1UcXELcwAyaMlntYNF9HbIqg" width="200" /></a></div>But a recent meta analysis of the trials have shown that norepinephrine might be better than Dopamine. It is associated with a 9% reduction in in-hospital and 28 day mortality in patients with septic shock. Patients on Dopamine had significantly increased incidence of cardiac arrhythmias compared to norepinephrine. This is probably the reason behind the poor performance of Doapmine...as we all know that arrhythmias can hinder cardiac function. The same finding of increased cardiac arrhythmias with Dopamine was also noted in the above SOAP trial.<br />
The above meta-analysis was done at Thomas Jefferson University.(<a href="http://www.ncbi.nlm.nih.gov/pubmed/21436167">J of Int Care Med ...March 2011</a>)<br />
<br />
Would be reasonable to use nor-epinephrine as the first line vasopressor for patients with septic shock. Infact according to the SOAP trial,dopamine was associated with an increased 28 day mortality in patients with cardiogenic shock, as compared to norepinephrine!<br />
<br />
</div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com10tag:blogger.com,1999:blog-809683702252526556.post-42464905234462162102011-04-23T19:34:00.000-04:002011-04-23T19:34:43.326-04:00The "Duty to warn" !!<div dir="ltr" style="text-align: left;" trbidi="on"><span style="font-family: Georgia, "Times New Roman", serif;">We had a young female with HIV for 10 years,who came with an infected condyloma. She has had previous MAC, vulval cancer and cervical dysplasia in the past. She has been with her partner for last 1 year, and they are sexually active,and use protection everytime. But when enquired, she said that the partner does not know about her HIV status , and she did not want to disclose this to him .Now.......do we have to honour her wish or...do we have to let the partner know?? Lets see what Connecticut law tells us.....(beware..this may not be true for other states!)</span><br />
<br />
<span style="font-family: Georgia, "Times New Roman", serif;">The term “duty to warn” refers to situations in which a physician may learn that a patient is engaging in unsafe sex without having disclosed his or her HIV-positive status to the partner. </span><br />
<span style="font-family: Georgia, "Times New Roman", serif;">Connecticut law permits both public health officers and physicians, under certain circumstances, to inform or warn partners that they may have been exposed to HIV.The term “partner” means an “identified spouse or sex partner of the protected individual or a person identified as having shared hypodermic needles or syringes with the protected individual.” The requirements for such a disclosure by a public health officer are that:</span><br />
<div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><a href="http://www.firstchoicesd.com/leather/images/disclosing_title.png" imageanchor="1" style="clear: right; cssfloat: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span style="color: #9fc5e8;"><img border="0" i8="true" src="http://www.firstchoicesd.com/leather/images/disclosing_title.png" /></span></a><span style="font-family: Georgia, "Times New Roman", serif;"><br />
</span></div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><span style="font-family: Georgia, "Times New Roman", serif;">1.There is a reasonable belief of a significant risk of transmission to the partner.</span></div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><span style="font-family: Georgia, "Times New Roman", serif;">2.The public health officer has counseled the individual regarding the need to notify a partner and reasonably believes that the individual will not disclose to the partner; and </span></div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><span style="font-family: Georgia, "Times New Roman", serif;">3.The public health officer has informed the protected individual of his or her intent to make the disclosure. </span></div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><span style="font-family: Georgia, "Times New Roman", serif;"><br />
</span></div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><span style="font-family: Georgia, "Times New Roman", serif;"><strong>A physician may only warn or inform a known partner if both the partner and the individual with HIV are under the physician’s care.</strong> A physician may also disclose confidential HIV related information to a public health officer for the purpose of warning partners, if the physician takes the same steps with respect to his or her patient as public health officers must take above.</span></div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><span style="font-family: Georgia, "Times New Roman", serif;">In making such a warning, the physician or public health official shall not disclose the identity of the HIV-infected individual and, where practicable, shall make such disclosure in person.</span></div><span style="font-family: Georgia, "Times New Roman", serif;">Well...this is still an evolving area of ethics, and might change in the future. Hope this helps.....and this is a sensitive issue to be dealt. </span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com1tag:blogger.com,1999:blog-809683702252526556.post-81433569061126659752011-04-15T19:21:00.000-04:002011-04-15T19:21:10.038-04:00Antihypertensives - a little pharmacology helps<div dir="ltr" style="text-align: left;" trbidi="on">I came across this article recently about some interesting facts about antihypertensive medications and their pharmacology, which I though will be useful for practising clinicians like us!<br />
The article describes about all 4 major types of antihypertensives. But the one which stands out is the angiotension converting enzyme inhibitors----WHY? due to their difference in pharcological actions compared to others.Let me start with a question..<br />
If Mr.X tolerates(no hypotension) 5mg of Lisinopril, can we increase the dose to 40mg straightaway?<br />
<div class="separator" style="clear: both; text-align: center;"></div><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiAWwqlbtzaiIN2G71cWs-2WIPn8LA6lnRuh5krEUXxsC7Mclff5aIiYzgpFDpB4FTip2jFFzIGW3PScbZlBtpGuQr3_8B9Uhd3f-1cCx1uKSPiBNlQ35qMmrQYQt2EeDFP5iCPYrX4On4/s1600/ace-i+dose+response.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="145" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiAWwqlbtzaiIN2G71cWs-2WIPn8LA6lnRuh5krEUXxsC7Mclff5aIiYzgpFDpB4FTip2jFFzIGW3PScbZlBtpGuQr3_8B9Uhd3f-1cCx1uKSPiBNlQ35qMmrQYQt2EeDFP5iCPYrX4On4/s400/ace-i+dose+response.png" width="400" /></a></div>Most of us would say "NO". But the author says yes....and the explanation is pretty simple, interesting and true!<br />
Unlike the other antihypertensives(beta blockers,CCB,diuretics), ace-i do not have a linear dose-response relationship....meaning that their BP lowering effect is not proportional to the dose. In other words....the efficacy of ace-i is the same irrespective of their dosage. Again...to make it more simple...a dose of 5mg of Lisinopril will lower the BP to the same extent as 40mg of Lisinopril. So why give 40mg in place of 2.5 mg? Well...the dose correlates with the duration of action.the higher the dose...the longer the duration of action!(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1463484/pdf/brjclinpharm00151-0068.pdf">Brit J Pharm 1984</a>!)<br />
It looks like...we have the low doses of ace-i in the market mainly to be used in patients with heart failure (who might have a low BP due to their other meds) to see if they can tolerate any hypotension induced by addition of ace-i. Also, the common side effect of ace-i...COUGH ..is not dose related.So here again..the dose doesnt matter.<br />
<br />
So the article concludes that..ace-i don't have a linear dose-response curve, and so their dose can be increased to the maximal dose without any major concerns for hypotension. But ...one aspect of ace-i that the article doesn't discuss...is <b>hyperkalemia</b>. Well..the risk of hyperkalemia with ace-i is dose related, and whether it would be a good idea to go for a maximal dose straightaway or to increase it gradually, in this aspect.<b>So..bottom line-----beacuse of the risk of hyperkalemia..we may not be able to go to a maximal dose directly, and not because of risk of hypotension.</b><br />
A quick word abt hyperkalemia with ace-i : the risk is quite low on its own. The risk is high in CKD(4 fold risk), hepatic disease(almost 5 fold risk), taking>15 tablets(5 to 9 fold risk), advanced age(twice likely)...<br />
(<a href="http://www.ncbi.nlm.nih.gov/pubmed/19255869">Pharm W Sci 2009</a>)<br />
<br />
Finally..the above article was published in <a href="http://www.ncbi.nlm.nih.gov/pubmed/21265580">American J of Cardio vasc Drugs 201</a>1. The graph(above) is a modified graph from the same study. </div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com0tag:blogger.com,1999:blog-809683702252526556.post-49455957210078054952011-04-14T20:14:00.001-04:002011-04-14T20:16:40.770-04:00Spontaneous bacterial peritonitis<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">An acute bacterial infection of ascitic fluid. Happens in people with ascites due to any etiology(even with CHF, Budd chiari !!!). The route of infection is still not entirely clear. It may be a simple translocation of bacteria from the gut due to bacterial overgrowth (as previously thought), or from hematogenous spread. But in general its the gut bacteria which accounts for most of SBP. This is mainly due to reduced intestinal transit times in pts with cirrhosis, along with low protein and complement levels etc.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">The common bugs are E.Coli, Klebsiella and Strep pneumoniae.</span><br />
<a href="http://t3.gstatic.com/images?q=tbn:ANd9GcQzbu_zUHjydvBhBRPZ1TtJgQvZVUaLyTtTXj0VxtNH1zkUZjFOig" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="140" src="http://t3.gstatic.com/images?q=tbn:ANd9GcQzbu_zUHjydvBhBRPZ1TtJgQvZVUaLyTtTXj0VxtNH1zkUZjFOig" width="200" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Diagnosis is based on diagnostic aspiration of the ascitic fluid. We all tap the ascitic fluid in someone with symptoms of infection(fever, abdominal pain, tenderness etc). But around 30% of pts with SBP might not have any symptoms!! So...what shall we do?.........One of our gastroenterologist says...."JUST TAP ALL ASCITES". Well...he might be right...given a mortality range of 30-70% for SBP!</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Based on the tap....it can be classified as follows...</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">1.SBP - if >250 PMN/micL AND positive culture.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">2.Culture-negative neutrocytic ascites -ascitic fluid culture is negative, but PMN count is ≥ 250 cells/µL. </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">3. Monomicrobial nonneutrocytic bacterascites - positive culture result with a PMN count ≤ 250 cells/µL.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Irrespective of what type it is!!!......they all need to be treated based on clinical suspicion.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">A very simple method being used these days(mostly in Europe) to diagnose SBP is the simple <b>Leukocyte esterase test</b>, which can be done at bedside. It has a sensitivity & specificity of 100 % & 91% resp to diagnose SBP! ( <a href="http://www.ncbi.nlm.nih.gov/pubmed/17353692">E Jof Gastro Hep 2007</a>)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><u>What to treat with</u> -- A 3rd generation Cephalosporin or a fluroquinolone. Its rare to have anaerobic SBP , as ascitic fluid is rich in Oxygen!</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><u>When to use albumin</u> - One of the main causes of mortality in SBP is due to development of renal failure. Albumin in addition to antibiotics have shown to prevent renal impairment and also to reduce mortality by around 10 to 15%based on this randomised trial(<a href="http://www.nejm.org/doi/full/10.1056/NEJM199908053410603#t=article">NEJM 1999</a>). Its given as 1.5 g/kg at diagnosis and 1 g/kg on Day3.There is another randomised trial underway in Brazil to add more evidence to this practice.(<a href="http://clinicaltrials.gov/ct2/show/NCT00852800">ALTERNATE trial</a>). </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><u>Prohylaxis for SBP</u> - Well..there are a group of patients who will benifit from prophylaxis. They are 1.anyone with a previous episode of SBP reducing mortality by 25% over a 1 year period(<a href="http://www.ncbi.nlm.nih.gov/pubmed/2210673">Hepatology 1990</a>) 2. GI bleed with a course of 7 days. 3.pts with ascitic fluid protein <1 g/dl plus one of the following --- creatinine >1.5, bilirubin>4.(<a href="http://www.blogger.com/Ciprofloxacin%20and%20long-term%20prevention%20of%20spontaneous%20bacterial%20peritonitis:%20results%20of%20a%20prospective%20controlled%20trial.">Hepatology 1995</a>) The last criteria is a soft call, and would depend on local practice.The last two indications are a short course(1 -2 weeks) of antibiotics.The first indication is a longer term prophylaxis (1 year or more). Norfloxacin 400 daily is a preferred drug(as it selectively targets Gram negatives, and leaves anaerobes !)</span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com0tag:blogger.com,1999:blog-809683702252526556.post-83899020190986649552011-04-12T21:56:00.001-04:002011-04-12T21:57:12.619-04:00Iron and Iron defeciency anemia - quick recap<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Eventhough we have read about Iron deficiency and anemia for a while now, we kind of need some reinforcements from time to time.(I....definitely need some!!). </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Lets start with the iron panel (well ...never forget to examine and correlate with the pt history & findings!)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-P-srhYBX-8LPrm30EV1OWIJ6-T91w2GrYlUmMm5hxvswBDQ4ixfz-EbwDcpE72awfpzENRHnNnncAiqeNkUWjfaw5KlyfrVwrRvf3SHckd7ACgjGuttnLALlggh5aB-yAtgQ1xieAbA/s1600/Iron.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="244" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-P-srhYBX-8LPrm30EV1OWIJ6-T91w2GrYlUmMm5hxvswBDQ4ixfz-EbwDcpE72awfpzENRHnNnncAiqeNkUWjfaw5KlyfrVwrRvf3SHckd7ACgjGuttnLALlggh5aB-yAtgQ1xieAbA/s320/Iron.png" width="320" /></a></div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>IRON PANEL</b> - A normal adult body contains 3-4 grams of iron; about 2 grams is stored in hemoglobin, about 400mg in iron-containing proteins, about 3-7 mg is bound to transferrin in plasma, and the remaining iron is </span><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">stored as ferritin and hemosiderin (an iron storage complex found within cells). Transferrin saturation(TSAT) & total iron binding capacity(TIBC) are 2 common tests done. TSAT essentially measures the same thing as TIBC. Total iron binding capacity indicates how much room there is for iron, while TSAT shows how much iron is currently saturating transferrin. Usually transferrin is about 1/3 full of iron: serum iron (Fe) divided by TIBC = 1/3. TSAT is reduced in patients with IDA and often in patients with anemia of chronic disease.</span><br />
<br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Ferritin is the cellular storage protein for iron in tissues found in the intestines, liver and spleen which contain approximately 20% iron.In general, TSAT < 20 &/or ferrtin<200ng/dl are considered to be iron deficient.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>CALCULATE IRON DEFICIT</b> - (especially if rapid replenishment is planned) - First, calculate the patient’s hemoglobin deficit by subtracting their current hemoglobin from the goal of 14g/dL. Second,calculate the body’s total hemoglobin deficit in grams by multiplying pts. weight by the normal blood volume of 65mL/kg.Tis gives the total hemoglobin deficit.There are 3.3mg of iron for each gram of hemoglobin in the blood. So,lastly, multiply the total hemoglobin deficit by 3.3mg to calculate iron deficit. </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<b><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">SOME FACTS ABOUT ORAL IRON REPLACEMENT</span></b><br />
<br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">*The recommended daily dose for the treatment of IDA in adults is 150-200 mg per day of elemental iron.(a 325mg FeSo4 tablet has 65mg iron, a 325mg ferrous fumarate has 106mg of iron)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">*It is best to give iron on an empty stomach ...as otherwise the iron binds with food in the stomach and impair</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">absorption; additionally, iron is best absorbed in an acidic environment.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">*Since Iron is absorbed in the duodenum, enteric coated tablets may not be useful.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">*After initiating oral iron, reticulocytosis will peak at 7-10 days in patients with moderate to severe anemia. *Hemoglobin levels begin to rise in 2 weeks. If taken in adequate doses, the hemoglobin would normalise by 8 - 10 weeks.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">*10 to 20% of patients will have GI side effects. So, a tablet with lower elemental iron may be tried.....or tablet may be tried with a small snack(accepting a somewhat reduced absorption)</span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com3tag:blogger.com,1999:blog-809683702252526556.post-83047131405971656052011-04-11T20:16:00.000-04:002011-04-11T20:16:11.617-04:00VRE ...when to treat!!<div dir="ltr" style="text-align: left;" trbidi="on"><div class="separator" style="clear: both; text-align: center;"></div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Vancomycin resistant enterococci are emerging as another leading nosocomial bacteria in hospitals.<span class="Apple-style-span" style="line-height: 18px;">Enterococci are gram-positive and facultatively anaerobic microorganisms commonly found as part of the normal flora in the gastrointestinal tract.</span><span class="Apple-style-span" style="line-height: 18px;">Several factors contribute to this increased risk among hospitalized patients, such as the disruption of the normal gastrointestinal flora by administration of broad-spectrum antibiotics, colonization with hospital-associated strains, poor infection control practices, presence of indwelling devices including urinary catheters, and an immunosuppressed state.<em>Enterococcus faecalis</em> and<em>Enterococcus faecium</em> are the two most common species isolated in this setting. </span><span class="Apple-style-span" style="line-height: 18px;">The most common types of infection caused by enterococci are urinary tract infections (UTIs)</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Given this intro...there may be 3 clinical scenarios we come across in hospital practice...</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">1. <b>VRE UTI</b> 2. a<b>ymptomatic VRE bactereuria </b> 3.<b>VRE colonization</b></span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Well ..these have to be differentiated in clinical practice, as the last 2 dont need treatment , except in some special circumstances.</span></span><br />
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjp34WJeyEWVymzrAOIw70RNvHigxBcMB4bx_z_YEeb4jDlyGHYusCb6nKB2qe5WbPAAjwUKQEItef2Pk7oKYqSaFqSqrI2Ao8VRUZK43NInZ2x1iWKr048RQI63vAC4Q4QWYL2t8Vbi-c/s1600/VRE.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="165" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjp34WJeyEWVymzrAOIw70RNvHigxBcMB4bx_z_YEeb4jDlyGHYusCb6nKB2qe5WbPAAjwUKQEItef2Pk7oKYqSaFqSqrI2Ao8VRUZK43NInZ2x1iWKr048RQI63vAC4Q4QWYL2t8Vbi-c/s320/VRE.png" width="320" /></a></div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"> A good detailed history about UTI symptoms in very much the deciding step for who to treat. Any lower or upper UTI system is needed to suspect UTI from VRE( except in elderly pts ). Once this is present, then proceed according to the flow sheet above.Evidence of VRE in the urine in the absence of symptoms or pyuria may have limited clinical importance in most patients, representing asymptomatic VRE bacteriuria or colonization, and generally does not require treatment; however, treatment may be considered in very high-risk patients (e.g., patients with catheter-acquired bacteriuria that persists 48 hrs after indwelling catheter removal, patients with planned genitourinary procedures, solid organ transplant recipients, neutropenic patients, and pregnant women).Always change Foley catheters once VRE is found in the urine.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"> Aminopenicillins, both with (e.g., ampicillin-sulbactam, amoxicillin-clavulanate) or without β-lactamase inhibitors and penicillin are generally considered to be the drugs of choice for the empiric treatment of VRE infections.In case of ampicillin resistance , then nitrofurantoin or Linezolid can be used for VRE cystitis...........and Daptomycin or Linezolid can be used for upper tract UTIs and VRE bactermia. Duration of treatment doesnt need to be extended beyond 14 days.</span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com8tag:blogger.com,1999:blog-809683702252526556.post-64377572128867165382011-04-10T00:13:00.000-04:002011-04-10T00:13:01.022-04:00The masks we (throw) use on patients .......<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="color: #4b4b4b; font-family: Verdana, sans-serif; font-size: 13px;"></span><br />
<div style="font-family: Verdana, sans-serif; font-size: 10pt; font-weight: normal;">Oxygen masks are effective oxygen delivery device which is used mainly to supply oxygen from a storage tank to the lungs. Many people make use of this nowadays most especially medical care providers, aviators, medical researchers and hyperbaric chamber and other patients. Because of this, a wide variety of styles are now available for oxygen masks.</div><div style="font-family: Verdana, sans-serif; font-size: 10pt; font-weight: normal;">There are four available basic styles of oxygen masks. These are the simple facemask, the venture mask, the partial rebreather mask and the non-rebreather mask.<br />
<br />
</div><div style="font-family: Verdana, sans-serif; font-size: 10pt;">The <b>simple facemask </b>is the most commonly available oxygen mask to the public. This has a number of vents on both sides and can deliver 35-40 percent of oxygen. However if the oxygen flow increases to 10L/min, this can deliver up to 50 percent oxygen. The disadvantage with this type of oxygen mask is that this seals poorly and has large ventilation holes, thus oxygen flow is diluted with air.<br />
<br />
</div><div style="font-family: Verdana, sans-serif; font-size: 10pt;"><a href="http://t3.gstatic.com/images?q=tbn:ANd9GcQlM47WPgyOB3FXVW_ZAaKb6cgxI_fhed1PFSlYPdzbdZejPmvO" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="http://t3.gstatic.com/images?q=tbn:ANd9GcQlM47WPgyOB3FXVW_ZAaKb6cgxI_fhed1PFSlYPdzbdZejPmvO" /></a>The <b>venture mask</b>, on the other hand, is an oxygen mask that uses a mechanical venturi effect in order to increase the flow rate of oxygen into the mask. It supplies a desired amount of oxygen starting from 24% upto 40%, and this amount can be adjusted by using different valves. Useful in COPD patients when you want to control the amount of O2 they receive.<br />
<br />
</div><div style="font-family: Verdana, sans-serif; font-size: 10pt;">Another type of oxygen mask is the <b>partial rebreather</b>. This type of mask, which is often called as medium concentration oxygen delivery mask, almost looks like the non-rebreather mask but it does not have a one-way valve between the mask and the reservoir bag. This delivers almost 40 to 50 percent oxygen, and can increase up to 60 percent. Dont use this in a patient with tendency towards Co2 retention.<br />
<br />
</div><div style="font-family: Verdana, sans-serif; font-size: 10pt;">The last type is the <b>non-rebreather</b>. From the four types, this is the one that can deliver up to 90 percent of oxygen. This makes use of valves on both sides in order to prevent air and patient exhalation from diluting the oxygen in the reservoir bag. The valves open when the patient inhales and breathes in oxygen. However, masks of this type with valves on both sides are prescription masks only.</div><div style="font-family: Verdana, sans-serif; font-size: 10pt; font-weight: normal;">These are the different styles of oxygen masks. All are able to deliver the amount of oxygen needed. These are effective if used in appropriate clinical setting!!</div></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com26tag:blogger.com,1999:blog-809683702252526556.post-16930391184698336932011-03-24T21:46:00.000-04:002011-03-24T21:46:26.048-04:00Calcium gluconate in a digitalised heart with hyperkalemia! OK...or..NOT OK???<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Today's morning report was about a young guy who was admitted with rhabdomyolysis, renal failure and hyperkalemia(K- 12mEq/dl) with sine wave pattern on his EKG. All this was due to a electrocution injury.So ...going through the management of hyperkalemia, someone pitched in the problem of giving Calcium gluconate in patients on Digoxin. Well....we had a couple of explanations for the interaction.So lets review the problem with these two drugs together.</span><br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGzBJUrmyhjocegOitV5s-4c7hlRjFzp9pmM-szPJly1YeXJGFEdZEt9fk6iHwJidw80tAcqWZPp_-glf-SWFM35qP8SxQGKeY1CM3bgO9PS6TdzMvdKO0uRIj181NTopTjI1-kJYk8V0/s1600/digoxin.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGzBJUrmyhjocegOitV5s-4c7hlRjFzp9pmM-szPJly1YeXJGFEdZEt9fk6iHwJidw80tAcqWZPp_-glf-SWFM35qP8SxQGKeY1CM3bgO9PS6TdzMvdKO0uRIj181NTopTjI1-kJYk8V0/s1600/digoxin.png" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">First.....the mechanism of action of Digoxin- Digoxin<span class="Apple-style-span" style="line-height: 18px;"> inhibits the Na<sup>+</sup>/K<sup>+</sup>-ATPase(exchanges 2 K for 3Na) in the cardiac myocyte by competing with potassium,and causes intracellular sodium concentration to increase. This then leads to an accumulation of intracellular calcium by blocking the Na<sup>+</sup>-Ca<sup>++</sup> exchange system. In the heart, increased intracellular calcium causes more calcium to be released by the <a href="http://cvphysiology.com/Cardiac%20Function/CF020.htm" style="color: #003a3a; text-decoration: underline;">s</a>arcoplasmic reticulum, thereby making more calcium available to bind to troponin-C, which increases contractility (inotropy).</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Second.....the mechanism of action of Calcium gluconate- a litlte more cellular pathology! . Normally the cardiac myocyte has a resting membrane potential(RMP is -90mV) and a threshold potential at which it is excited(TP is-75mV).So a 15mV depolarisation is needed to excite the myocyte. In hyperkalemia, the RMP becomes less negative (-80mV) , but the TP remains at -75mV. This means that ..now..only a 5mV depolarisation is enough to excite the myocyte. This is the cause of hyperexcitability leading to arrhythmia.Calcium gluconate...by increasing Ca transport across the membrane reduces the TP from -75mV to around -65mV ...restoring the 15mV depolarisation needed to excite the myocyte. (the numbers in mV are just an example) ...... <a href="http://www.annemergmed.com/article/S0196-0644(10)00634-7/fulltext">Annals of Emer Med 201</a>1</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Sooo...in patients on Digoxin(which causes positive inotropy through calcium)...if more calcium is given....it can lead to more intracellular calcium in mycocyte leading to what has been described as cardiac tetany due to prolonged depolarisation. So ,does hyperkalemia make this process worse?? Well, probably not. ------Since K+ and digoxin compete for Na/KATPase, the binding depends on the concentration of the two. In hyperkalemic state...K+ binds preferentially than digoxin, on Na/K ATPase, and thus resulting in diminished digoxin action. (to better understand...think about hypokalemic states...where digoxin will bind preferentially to the receptor, and hence result in digoxin toxicity!--which is well known)</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">A slightly different scenario would be...when some one(with no K+ problems) takes too much digoxin...which will also result in digoxin binding preferentially than K+, to Na/KATP ase resulting in Dig toxicity. In this setting....pt may go hyperkalemia..as more K+ ends up extracellularly (due to not binding with Na/K ATPase), and if this patient gets Ca gluconate..then again..it can causes arrhythmias.</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>Bottom line is...if Calcium is given(and pt made hypercalcemic) to any pt on Digoxin ..there is a increased possibility for cardiac arrhythmias(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1741346/pdf/v075p00554.pdf">PG Med J 1999</a>) ...irrespective of whether they have hyperkalemia or not. </b></span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Whether these pathophysiologies!! are clinically relevant is not clear, as these interactions are based on few case reports only. Have a look at this animal study (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15461240">J clin Tox 2004</a>) and this retrospective study on pts ..over 18 years from a hospital in Arizona(<a href="http://download.journals.elsevierhealth.com/pdfs/journals/0736-4679/PIIS0736467908009104.pdf">J Emer Med 2011</a>).Both of them show no clinically relevant interaction of Calcium administration even in Digoxin toxicity. !!!!!!!</span></span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com11tag:blogger.com,1999:blog-809683702252526556.post-43968802918672764792011-03-02T12:38:00.000-05:002011-03-02T12:38:05.786-05:00Some key aspects of Surviving sepsis<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">The key recommendations covering all aspects of sepsis treatment were outlined in the 2008 update on Surviving sepsis campaign. This is a tribute to my 2 month CU rotation which I completed this week.....</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>E</b>arly goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C)</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>B</b>lood cultures before antibiotic therapy (1C);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b> I</b>maging studies performed promptly to confirm potential source of infection (1C); </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>A</b>dministration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b> R</b>eassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7–10 days of antibiotic therapy guided by clinical response (1D);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>S</b>ource control with attention to the balance of risks and benefits of the chosen method (1C);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>A</b>dministration of either crystalloid or colloid fluid resuscitation (1B);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b> F</b>luid challenge to restore mean circulating filling pressure (1C); </span><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); <b>V</b>asopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure ≥65 mm Hg (1C);</span><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b> S</b>tress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>R</b>ecombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients).</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>I</b>n the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7–9 g/dL (1B);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>A</b> low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>A</b>pplication of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1C); head of bed elevation in mechanically ventilated patients unless contraindicated (1B); avoiding routine use of pulmonary artery catheters in ALI/ARDS (1A);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>T</b>o decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patients with established ALI/ARDS who are not in shock (1C);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>P</b>rotocols for weaning and sedation/analgesia (1B); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>I</b>nstitution of glycemic control ,</span><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> targeting a blood glucose <150 mg/dL after initial stabilization (2C);</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"> <b>E</b>quivalency of continuous veno-veno hemofiltration or intermittent hemodialysis (2B); </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">prophylaxis for deep vein thrombosis (1A); </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><b>U</b>se of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (1D).</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Our hospital has a Sepsis alert system whereby anyone getting into ER with tachycardia and fever will be eligible for a STAT call to the ICU resident (which was unfortunately 'I' for the last 2 months!!). </span><a href="http://www.survivingsepsis.org/About_the_Campaign/Documents/Final%2008%20SSC%20Guidelines.pdf">http://www.survivingsepsis.org/About_the_Campaign/Documents/Final%2008%20SSC%20Guidelines.pdf</a><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
</div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com2tag:blogger.com,1999:blog-809683702252526556.post-56369172489725235012011-02-12T22:18:00.000-05:002011-02-12T22:18:30.858-05:00complications during rewarming<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Therapeutic rewarming is being used widely in patients after a cardiac arrest (irrespective of type of cardiac arrest). Earlier the patient is cooled ..better the neurological outcome. Usually we keep them under hypothermia for 24 hours. Then comes the period of rewarming, which can be safely done by reducing the body temperature by 0.3 - 0.5 C /hr...and the aim is to normalise body temparature by 8 hours after starting to rewarm. Hemodynamic instability /electrolyte derangements/ arrhythmias can occur during this period...and should be addressed sooner than later.</span><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://t3.gstatic.com/images?q=tbn:ANd9GcSNWRGInX9I4mOPCZH5Zpg6JeJbCCrOWM1Ot_etXaNFlcU2b0JS-w" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://t3.gstatic.com/images?q=tbn:ANd9GcSNWRGInX9I4mOPCZH5Zpg6JeJbCCrOWM1Ot_etXaNFlcU2b0JS-w" /></a></div><b><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Medications During Rewarming</span></b><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Maintain sedation until a temperature of 35° C (95° F) is reached.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">- If a neuromuscular blocking agent is infusing solely to prevent shivering, discontinue the neuromuscular blocking agent before the sedative/analgesic agents.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">- Do not discontinue the sedative/analgesic until the patient is moving or until the neuromuscular blocking agent has been discontinued for at least 3 to 5 half lives of the paralytic.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<b><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Hemodynamics</span></b><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Monitor patient for hypotension. This is secondary to peripheral vasodilatation induced by rewarming. Gentle i.v fluids helps with this issue. Its physiologically reasonable ..not to use Ringer Lactate in this situation, as the hypothermic liver would not be able to metabolise lactate. Try to avoid vasopressors like dopamine during this period..due to the cardiac excitability from these drugs. Again ...physiologically phenylephrine would make more sense as it does not have a beta activity..and only has alpha atction.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<b><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Electrolytes</span></b><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Discontinue potassium infusions during rewarming as potassium moves out of cells into the extracellular space.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Acetaminophen and external cooling p.r.n. to keep temperature less than 37.5° C (99.5° F) for 48 hours after warming. </span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com8tag:blogger.com,1999:blog-809683702252526556.post-25783643923675147732011-01-28T23:03:00.002-05:002011-01-28T23:06:18.129-05:00Fondaparinux(Arixtra) and a word of caution<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Fondaparinux is being used widely for anticoagulating patients in the acute setting (MI, PE,DVT etc). It has quite a few advantages over heparin and other low molecular weight heparins. Lets quickly see how it works.</span><br />
<div class="separator" style="clear: both; text-align: center;"></div><div class="separator" style="clear: both; text-align: center;"></div><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjHaZn5QXW7SQP0PsNFnrCRcBFeL8zvaaE6lu8YDaYpqDkP-RIlOEcn73RL0xzC8BOt7zu5rxwP2OXHe6C1ql7itr82qxxypPSkKWOpzsHl0EURcoJQ04-TOn50hSeX8RdUuOEc14m-kvA/s1600/arixtra.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="192" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjHaZn5QXW7SQP0PsNFnrCRcBFeL8zvaaE6lu8YDaYpqDkP-RIlOEcn73RL0xzC8BOt7zu5rxwP2OXHe6C1ql7itr82qxxypPSkKWOpzsHl0EURcoJQ04-TOn50hSeX8RdUuOEc14m-kvA/s320/arixtra.png" width="320" /></a></div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">Fondaparinux is a completely synthetic pentasaccharide. It is an indirect ,selective Factor Xa inhibitor.</span><span class="Apple-style-span" style="line-height: 18px;"> It inhibits factor Xa activity indirectly through binding and activating antithrombin III. </span><span class="Apple-style-span" style="line-height: 18px;">Fondaparinux is not consumed in this reaction but instead is released from the inhibitory complex once binding of antithrombin III to factor Xa has occurred. In this way , by binding to 1 ATIII molecule,it can inhibit nearly 50 factor Xa molecules. It does not bind to other plasma proteins.</span><span class="Apple-style-span" style="line-height: 18px;">predictable dose response that is independent of age or sex.It does not bind with platelet factor 4(PF4) , and hence doesnt cause thrombocytopenia (as caused by heparin- HIT).</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Fondaparinux has nearly complete bioavailability after subcutaneous injection. The pharmacokinetics of fondaparinux appears predictable and consistent independent of age or sex. The peak plasma level is obtained about 2 h after the subcutaneous injection, indicating that a rapid onset of antithrombotic activity is obtained on initiation of treatment. The elimination half-life is about 17 h and it is dose-independent, which allows a convenient once-daily dosing regimen. Fondaparinux is eliminated exclusively by the kidneys.</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span></span><br />
<span class="Apple-style-span" style="line-height: 18px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">This last property of being excreted by kidneys makes it a riskier agent in patients with renal failure...and it is contraindicated for patients with GFR < 30ml/hr(as risk of bleeding in this group is around 7.5%,compared to 0.1-0.4% in pts with GFR>80ml/hr). This is for patients with stable kidney function. A considerable proportion of patients for whom we prescribe Fondaparinux (until we confirm or refute the diagnosis of PE/DVT or NSTEMI) also have acute renal failure. In these instances the kidney's actual GFR is less than the reported GFR from the MDRD formula(as the production and excretion of creatinine is not in a steady state any more). So its possible to have a MDRD GFR as>30ml/min.....but with an actual GFR lot less than 30ml/min.......in which case giving Fondaparinux might be a disaster (because of a 17hr half life.....it lasts for 2-4 days in normal individuals. looonger in pts with AKI!) It would be reasonable to first think twice..whether this patient needs acute anticoagulation...and if yes..then to consider unfractionated heparin in someone with acute renal failure. </span></span></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com1tag:blogger.com,1999:blog-809683702252526556.post-52390492333922146422011-01-24T17:34:00.002-05:002011-01-28T23:07:14.235-05:00Does Cranberry Juice Prevent Recurrent UTI ?<div dir="ltr" style="text-align: left;" trbidi="on"><div style="font-family: Georgia,'Times New Roman',serif; text-align: left;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjGC5IB-kSYOoluCVjLdNkx7T5xA2LRpeouTnokclFj087qzgiNhIwxkCUwxn7lKj1O2hDBvNI5jpD1Mwuqv1aePvsHvda67kJnaGjyLxUicrucCViqT_jwd859DKKTzU2X42cCkVg6vMg/s1600/cranberry.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjGC5IB-kSYOoluCVjLdNkx7T5xA2LRpeouTnokclFj087qzgiNhIwxkCUwxn7lKj1O2hDBvNI5jpD1Mwuqv1aePvsHvda67kJnaGjyLxUicrucCViqT_jwd859DKKTzU2X42cCkVg6vMg/s1600/cranberry.png" /></a><span style="font-size: small;"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"> </span></span></b><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"></span></span></b></span><br />
<h3 style="font-weight: bold; margin-bottom: 2px; margin-top: 5px;"><span style="font-size: small;"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><span class="Apple-style-span"><div style="font-weight: normal;"><h3 style="font-weight: bold; margin-bottom: 2px; margin-top: 5px;"><span style="font-size: small; font-weight: normal;">As we all know....cranberry juice has been thought to prevent UTIs. No we have a randomised controlled trial to answer the above question. Reasearchersa at Michigan conducted a double blind trial on women 18 - 40 years of age who presented with with UTIs over a 2 year period.</span></h3><div><span style="font-size: small; font-weight: normal;"><br />
</span></div><span style="font-size: small;">There were 319 participants who were randomized to receive 8 ounces twice daily of placebo juice or of low-calorie cranberry juice cocktail standardized for its concentration of proanthocyanidin (the active ingredient). A clean-catch urine sample was collected for culture at baseline, 3 months, and 6 months, and at visits associated with UTI episodes. During the 6-month follow up, 54 culture-confirmed recurrent UTI episodes were observed. The recurrence rate — 16.9% overall — was 19.3% in the cranberry juice group and 14.6% in the placebo group (<i>P</i>=0.21).</span></div><div style="font-weight: normal;"><span style="font-size: small;"><br />
</span></div><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><span style="font-size: small;">These findings and the don't show any reduction in the recurrence of UTI among reproductive age group females. However, as the authors point out, something other than proanthocyanidin might be the active factor, and the placebo might inadvertently have contained this ingredient. Therefore, this study is probably not the last nail on cranberry juice and UTI prevention.In fact the </span><a href="http://www2.cochrane.org/reviews/en/ab001321.html"><span style="font-size: small;">2008 cochrane review</span></a><span style="font-size: small;"> </span></span></span></span><span class="Apple-style-span"><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><a href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD001321/frame.html"><span style="font-size: small;"> <span style="color: black;"></span></span></a><span style="font-size: small;">showed a small reduction in UTI over a 12 month period.</span></span></span></span></span></span></b></span></h3><div style="margin-bottom: 10px; margin-top: 2px;"><span style="font-size: small;"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><i><br />
</i></span></span></b></span></div><div style="margin-bottom: 7px; margin-top: 10px;"><span style="font-size: small;"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><span style="font-family: Georgia, 'Times New Roman', serif;">After an initial urinary tract infection (UTI), 24% of otherwise healthy women aged 18 to 39 experience a recurrence within 6 months, and 5% of women have multiple recurrences within 1 year. Cranberry juice is a well-known folk remedy for preventing UTI, and in vitro experiments have suggested that cranberries decrease the adherence of<span class="Apple-converted-space"> </span><i>Escherichia coli</i> to the uroepithelium. </span></span></span></b></span></span></b></span><br />
<span style="font-size: small;"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"></span></span></span></span></b></span><br />
<h3 style="font-weight: bold; margin-bottom: 2px; margin-top: 5px;"><span style="font-size: small;"><b><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span"><span class="Apple-style-span"><span class="Apple-style-span" style="border-collapse: separate; color: black; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span">All this study shows is that proanthocyanidin may not be the active ingredient behind UTI prevention ! Given the inability to prove or disprove this theory........it will be ok to take cranberry juice....as it doesnt cause any harm.</span></span></span></span></span></b></span></h3></div></div></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com3tag:blogger.com,1999:blog-809683702252526556.post-18954759378399468752011-01-18T22:14:00.000-05:002011-01-18T22:14:46.961-05:00angioedema risk with ace-inhibitors<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">We recently had an african american male presenting with swollen tongue, lips and a stridor. was intubated for airway compromise..given epinephrine im, benadryl, ranitidine, hydrocortisone. Was extubated the next day after resolution of edema. This gentleman was started on Lisinopril 2 weeks ago for hypertension. This is likely...to be Angioedema due to ace-i!!</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">The pathophysiologic mechanism of angioedema with regard to ACE inhibitor therapy is believed to relate to the kallikrein-kinin plasma effector system. B</span><span class="Apple-style-span" style="line-height: 18px;">radykinin, which is normally degraded by kininase II/ACE, accumulates in tissues pts on ace-i. </span><span class="Apple-style-span" style="line-height: 18px;"> P</span><span class="Apple-style-span" style="line-height: 18px;">lasma bradykinin has been shown to increase up to 12-fold during acute angioedema attacks in patients with hereditary or acquired forms of angioedema. A <a href="http://archderm.ama-assn.org/cgi/content/abstract/133/8/972">case control study from 1997</a> showed consistently </span><span class="Apple-style-span" style="line-height: 18px;">decreased levels of carboxypeptidase N(kininase1) and C1 esterase inhibitor in pts with angioedema secondary to ace-i Vs pts without angioedema on ace-i.</span></span><br />
<br />
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhPK7zD_BUBI7W5TAh4geszBurxAZXASI5_hM-TQBvP8GjzkLqR9SrvHI2d-JpBiwtU3pA8d8RQ4r_Pcg6MJ3n1YtcD6Co-2bLM_nMmOlWRNYcuS61tmVAEEPu_dF1cC8wsMkt94UAYzw/s1600/angioedema.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="203" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhPK7zD_BUBI7W5TAh4geszBurxAZXASI5_hM-TQBvP8GjzkLqR9SrvHI2d-JpBiwtU3pA8d8RQ4r_Pcg6MJ3n1YtcD6Co-2bLM_nMmOlWRNYcuS61tmVAEEPu_dF1cC8wsMkt94UAYzw/s320/angioedema.png" width="320" /></a></div><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;">Another interesting theory has been the association of low levels of dipeptidyl peptidase 4( known to catabolise bradykinin) in pts with ace-i associated angioedema. (<a href="http://hyper.ahajournals.org/cgi/content/full/39/2/460">Hypertension 2002</a>). The reason this is interesting is because ..... the recent DPP-4 inhibitors(Sitagliptin, Saxagliptin) that we use for diabetes work by inhibiting DPP-4. So if the above theory is true..then we might see an increased risk of angioedema in patients on these medications along with ace-i(as most diabetics need ace-i). Lets wait and see!!!!</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">Several risk factors for development of angioedema with ace-i have been proposed.</span><span class="Apple-style-span" style="line-height: 18px;">The most important predisposing risk factor, evidenced by case-control studies, appears to be ethnic differences.</span><span class="Apple-style-span" style="line-height: 18px;">The risk of angioedema with ACE inhibitors is higher in blacks and appears not to be related to dose, specific ACE inhibitors, or concomitant medications...as shown in this nice case control study(<a href="http://www.nature.com/clpt/journal/v60/n1/full/clpt1996442a.html">Clin Pharm & Ther 1996</a>). Other risk factors are </span><span class="Apple-style-span" style="line-height: 18px;">a history of idiopathic angioedema,</span><span class="Apple-style-span" style="line-height: 18px;"> </span><span class="Apple-style-span" style="line-height: 18px;">head and neck surgery, and seafood allergy. </span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;"></span><span class="Apple-style-span" style="line-height: 18px;">This study from 1988 ...which looked at 3 studies...each with 12,0000 patients.....showed that the incidence of angioedema is high in the first week of starting Enalapril...and then declined. But p</span><span class="Apple-style-span" style="line-height: 18px;">revious tolerance to an ACE inhibitor does not exclude the risk for angioedema when therapy is modified to a different ACE inhibitor. Finally...the oberall incidence of angioedema with ace-i is around 0.1 - 0.6% over a period of 6 months (a rough estimate based on studies like <a href="http://www.ncbi.nlm.nih.gov/pubmed/14751650">OCTAVE </a> (again showing a higher incidence among African americans than other races)</span></span>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com25tag:blogger.com,1999:blog-809683702252526556.post-4651999637549641712011-01-10T20:01:00.001-05:002011-01-10T22:02:18.801-05:00Amiodarone and hyperthyroidismAmiodarone therapy causes thyroid dysfunction in 14 to 18% of the involved patients. Therefore, before initiation of such therapy, patients should have a baseline TSH measurement, and then they should be monitored at 6-month intervals during treatment. <br />
<div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><a href="http://www.google.com/imgres?imgurl=http://download.eclips.consult.com/ec/images/journalimages/0084-3741/PIIS0084374108703615.gr1.sml.gif&imgrefurl=http://www.eclips.consult.com/eclips/article/Endocrinology/S0084-3741(08)70361-5&usg=__UP3knHmHxnoKOOLMlwhIjcWqm5w=&h=93&w=108&sz=2&hl=en&start=1&zoom=1&um=1&itbs=1&tbnid=2sz3W3qoo4b1uM:&tbnh=73&tbnw=85&prev=/images%3Fq%3Damiodarone%2Band%2Bthyroid%26um%3D1%26hl%3Den%26sa%3DN%26rls%3Dcom.microsoft:en-us%26tbs%3Disch:1" style="clear: right; cssfloat: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a>In patients receiving amiodarone, either hypothyroidism, which is treated with levothyroxine replacement, or hyperthyroidism may develop. </div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><br />
</div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><a href="http://www.google.com/imgres?imgurl=http://www.nnmedtas.com.au/images/procedures/thyroid.jpg&imgrefurl=http://www.nnmedtas.com.au/procedures/thyroid.htm&usg=__puLRuo7Yc5IuoOGLfrlM1Lzuu3Y=&h=517&w=519&sz=63&hl=en&start=13&zoom=1&um=1&itbs=1&tbnid=McV6zhT_dWMrlM:&tbnh=130&tbnw=131&prev=/images%3Fq%3Damiodarone%2Band%2Bthyroid%26um%3D1%26hl%3Den%26sa%3DN%26rls%3Dcom.microsoft:en-us%26tbs%3Disch:1" style="clear: right; cssfloat: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img height="132" src="http://t2.gstatic.com/images?q=tbn:McV6zhT_dWMrlM:" style="border-bottom: #ccc 1px solid; border-left: #ccc 1px solid; border-right: #ccc 1px solid; border-top: #ccc 1px solid; padding-bottom: 1px; padding-left: 1px; padding-right: 1px; padding-top: 1px; vertical-align: bottom;" width="133" /></a>Amiodarone-induced hyperthyroidism is of two types. </div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><strong>Type 1</strong> is similar to iodine-induced hyperthyroidism (jodbasedow phenomenon) and manifests with a low TSH level, a high free T4or T3estimate, and a low radioiodine uptake. Doppler ultrasonography shows increased vascularity of thyroid tissue, similar to that in Graves’ disease. Because of low radioiodine uptake, 131I treatment cannot be used, and use of antithyroid drugs has yielded only varied success. Although mild cases have resolved even when amiodarone therapy has been continued, consideration of ceasing this drug treatment is recommended. Restoration of euthyroidism may take months after cessation of amiodarone therapy. </div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><br />
</div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><strong>Type 2</strong> amiodarone-induced hyperthyroidism resembles a destructive thyroiditis. Laboratory values and radioiodine uptake are similar to the findings in type 1; however, Doppler ultrasonography shows decreased vascularity of the thyroid tissue. Corticosteroid treatment is recommended, and patients sometimes require surgical removal of the thyroid.</div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;"><br />
</div><div style="border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none;">Wherever possible its better to avoid ..than to treat this complication!!</div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com1tag:blogger.com,1999:blog-809683702252526556.post-22776964124952825222011-01-06T18:02:00.000-05:002011-01-06T18:02:42.771-05:00CT scan for lung cancer screening<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">The National Lung Cancer Screening trial (NSLT) ..comparing two ways of detecting lung cancer- low dose helical CT Vs regular chest xray was stopped in Nov 2010 , after the results showed a dramatic reduction in mortality!</span><br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjsueCYRVmiUXdY6OkT5Wonsb7lKDq1a0mfa3pskeefzSESK33Qr7qqJIf4CbvzxeGqBcRE89Qx4_BeKIIDFCMK1ur4Npm0-6wpOBfDwnq-qcxlG1J16jYEDSTf_PIv9cUYiUAxKJAGoNM/s1600/lung+cancer.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="183" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjsueCYRVmiUXdY6OkT5Wonsb7lKDq1a0mfa3pskeefzSESK33Qr7qqJIf4CbvzxeGqBcRE89Qx4_BeKIIDFCMK1ur4Npm0-6wpOBfDwnq-qcxlG1J16jYEDSTf_PIv9cUYiUAxKJAGoNM/s200/lung+cancer.png" width="200" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><br />
</span><br />
<span class="Apple-style-span" style="border-collapse: separate; color: black; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px; text-align: left;">The trial began in 2002 and involved more than 53,000 current and former heavy smokers(quit within last 15 years) 55 to 74 years of age. Individuals were randomized to undergo screening annually for 3 years with either CT or chest x-rays, and were then followed for another 5 years.</span></span><br />
<span class="Apple-style-span" style="border-collapse: separate; color: black; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px; text-align: left;">The results, which were reviewed by the trial's Data and Safety Monitoring Board on October 20, show a statistically significant difference in lung cancer mortality in the 2 groups, which led to the trial being halted. There were 354 lung cancer deaths among those who underwent CT screening and 442 among those who underwent chest x-ray.This is a 20% reduction in mortality in patients who underwent screening with CT scan. This is an impressive finding....but the study has not been published yet. Questions do remain......who is at high risk? and who needs CT scan? There will also be a problem with false positivies, as with any other screening test. So will be interesting to see the cut off criteria for doing a screening CT scan.</span></span><br />
<span class="Apple-style-span" style="border-collapse: separate; color: black; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px; text-align: left;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="border-collapse: separate; color: black; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="line-height: 18px; text-align: left;">Thus far, there has been no recommendation for lung cancer screening from any authority, but these new data might be a turning point.</span></span><span class="Apple-style-span" style="border-collapse: separate; color: black; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="line-height: 18px; text-align: left;"> </span></span><span class="Apple-style-span" style="border-collapse: separate; color: black; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="line-height: 18px; text-align: left;"> Keeping in mind that Lung cancer is the leading cause of cancer mortality in US and worldwide....screening will help reduce the associated mortality. But the most important intervention that will reduce mortality will be staying away from Tobacco!!</span></span></span>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com26tag:blogger.com,1999:blog-809683702252526556.post-31770843165328479362011-01-04T22:39:00.001-05:002011-01-05T01:12:27.878-05:00urinary calcium and renal stones<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjXgoDZUdNogrwd7iPtwog6Oih3n8tzH7kHMvZy8iGUnQ6B8LqlYs-qIjNp7bA0etzUf_je94EvgwpvwAlzx2YWZzlRTHnjv8wf_IyfSB3Patril1o7C6SpC1FGG3HDRWWz4tz3tA8Ihc8/s1600/stone.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjXgoDZUdNogrwd7iPtwog6Oih3n8tzH7kHMvZy8iGUnQ6B8LqlYs-qIjNp7bA0etzUf_je94EvgwpvwAlzx2YWZzlRTHnjv8wf_IyfSB3Patril1o7C6SpC1FGG3HDRWWz4tz3tA8Ihc8/s1600/stone.png" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;">Calcium oxalate stones are the most common type of renal stone.(around 75%). 3 types of stones can be caused by calcium- <span class="Apple-style-span" style="line-height: 18px;">calcium oxalate, CaCO</span><span class="Apple-style-span" style="line-height: 18px;"><sub>3</sub></span><span class="Apple-style-span" style="line-height: 18px;">, or CaHPO</span><span class="Apple-style-span" style="line-height: 18px;"><sub>4</sub></span><span class="Apple-style-span" style="line-height: 18px;">. </span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;"></span><span class="Apple-style-span" style="line-height: 18px;">Calcium oxalate crystals can form at any pH and have various microscopic morphologies. It is estimated that about half of the oxalate in urine comes from ascorbic acid (vitamin C), which is a precursor to oxalate. Calcium oxalate crystals are also associated with ethylene glycol ingestion, another oxalate precursor. Calcium carbonate (CaCO</span><span class="Apple-style-span" style="line-height: 18px;"><sub>3</sub></span><span class="Apple-style-span" style="line-height: 18px;">), the main component of marine shells and egg shells, can be found as small granular crystals in alkaline urine. Calcium carbonate crystals are not common in urine but when present can be mistaken for bacteria.</span><span class="Apple-style-span" style="line-height: 18px;"> Calcium phosphate (CaHPO</span><span class="Apple-style-span" style="line-height: 18px;"><sub>4</sub></span><span class="Apple-style-span" style="line-height: 18px;"> </span><span class="Apple-style-span" style="line-height: 18px;">or Ca[H</span><span class="Apple-style-span" style="line-height: 18px;"><sub>2</sub></span><span class="Apple-style-span" style="line-height: 18px;">PO</span><span class="Apple-style-span" style="line-height: 18px;"><sub>4</sub></span><span class="Apple-style-span" style="line-height: 18px;">]</span><span class="Apple-style-span" style="line-height: 18px;"><sub>2</sub></span><span class="Apple-style-span" style="line-height: 18px;">) crystals can have different morphologies depending on their state of hydration and can be present in the urine sediment of neutral or slightly alkaline or acidic urine.</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">Eventhough calcium is involved in majority of stones....its measurement in urine is of limited value in predicting/diagnosing renal stones.This is because of a lot of other factors involved in stone formation( citrate, oxalate, urine Ph etc). Risk assessment using ratios </span><span class="Apple-style-span" style="line-height: 18px;">such as the calcium/magnesium ratio, the calcium/citrate ratio, and the (calcium * oxalate)/(magnesium * citrate) ratio have met with little success, and are regarded to play a supplementary role in evaluation of renal stones.( <a href="http://www.ncbi.nlm.nih.gov/pubmed/19333626">Ped Nephrol 2009</a>)</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">But Urine calcium can be used in assessing patients with primary hyperparathyroidism. A study done comparing biochemical parameters and treatment outcomes in stone formers with hyperparathyroidism Vs those without systemic disease...found ..a greater amount of calcium excretion in urine of stone formers with hperparathyroidism than in stone formers without systemic disease.(<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08064.x/pdf">Brit J of Urol 2009</a>) .Thus high Calcium creatinine clearance rate(or calcium creatinine ratio > 0.20) can be helpful in patients with hyperparathyroidism in predicting/assessing risk for stone formation. </span><span class="Apple-style-span" style="line-height: 18px;">Interestingly, parathyroidectomy did not reverse the hypercalciuria or hypophosphatemia in these patients.</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;">Increased Urinary calcium - > 300mg/24 hours</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;">Increased calcium creatinine ratio - > 0.2 </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">A quick word about diet in calcium stones---- is reducing calcium in diet doesnt help( again because of multiple factors involved in stone formation). But reducing oxalate consumption prevents crystal formation and reduces stone formation.Have a look at this article from <a href="http://www.nejm.org/doi/full/10.1056/NEJM200201103460202">NEJM 2002</a> (hope u all have access)</span></span>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com4tag:blogger.com,1999:blog-809683702252526556.post-64042097456754429682011-01-02T23:57:00.000-05:002011-01-02T23:57:32.612-05:00Red flags in evaluation of syncope<a href="http://t2.gstatic.com/images?q=tbn:ANd9GcTZ2v1W2uiomDZ_NViGhMk1WkmsNRUKDEZUVWgRR5L9a26jroIpaQ" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="200" src="http://t2.gstatic.com/images?q=tbn:ANd9GcTZ2v1W2uiomDZ_NViGhMk1WkmsNRUKDEZUVWgRR5L9a26jroIpaQ" width="156" /></a><span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">Syncope is one of the commonest presentation to the ERs....and would require substantial spending if everyone gets a complete work up to diagnose or rule out the causes. It would be reasonable to risk stratify patients and investigate. The first step would be to get the definition of syncope right! -----</span><i><span class="Apple-style-span" style="line-height: 18px;"> It is a transient loss of consciousness due to transient global hypoperfusion of brain. </span></i></span><br />
<span class="Apple-style-span" style="font-family: arial, sans-serif;"><i><span class="Apple-style-span" style="font-size: x-small;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span></i></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif;"><span class="Apple-style-span" style="line-height: 18px;">Not everyone needs admission or specialist referral<i>. </i></span><span class="Apple-style-span" style="line-height: 18px;">Urgent referral or hospital admission for investigation is needed for patients who have chest pain, breathlessness, a history of cardiac disease, family history of sudden death, signs of heart failure, or abnormalities on electrocardiography. The electrocardiography features that suggest cardiac arrhythmias include ventricular tachycardia, a widened QRS complex (>120 ms), sinus bradycardia (<50 beats/min), prolonged or excessively shortened corrected QT interval (>450 ms and < 300 ms, respectively), T wave inversion leads V1–V3, epsilon waves or ventricular late potentials (arrhythmogenic right ventricular dysplasia), and right bundle branch block with ST elevation and T wave inversion in V1–V3 (Brugada syndrome). Patients who report a history of syncope with no warning symptoms (Stokes-Adams attack), syncope during exercise, palpitations preceding syncope, and syncope in the supine position should be investigated by a specialist. People with frequent or injurious syncope or implications for driving also warrant specialist input. Prolonged unconsciousness, confusion after the event, or neurological signs and lateral tongue biting suggest a non-syncopal event, and this should prompt neurological evaluation</span></span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;">To simplify the above, San Fransisco Syncope Rule was developed .SFSR uses the presence of an abnormal electrocardiogram(any new rythm changes or presence of an abnormal rythm), heart failure(or a c/o shortness of breath), anaemia (haematocrit < 30%), or systolic hypotension (< 90 mm Hg) to identify patients who require urgent action. In the <a href="http://www.annemergmed.com/article/S0196-0644(03)00823-0/abstract">original derivation study, the SFSR</a> had 96% (92% to 100%) sensitivity and 62% (58% to 6%) specificity in identifying patients with short term adverse outcomes. In the study where the <a href="http://www.ncbi.nlm.nih.gov/pubmed/16631985">SFSR score was validated</a>, it showed a 98% sensitivity and 58% specificity in identifying patients with short term (1 month) mortality. And it had the ability to decrease overall admissions by 7%. A thing to remember in this study..was that the rule was applied after the ER physician has evaluated the patient. So would be optimal for an Internal medicine resident seeing a ER consult.</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;">The reason behind paying special attention to cardiac causes are...cardiac syncope carries a high mortality in all age groups. The Framingham study cohort's age and sex adjusted hazard ratios for death over a mean follow-up of 8.6 years was 2.4 (95% confidence interval 1.78 to 3.26) for cardiac syncope compared with 1.17 (0.95 to 1.44) in the "vasovagal group," which included orthostatic hypotension. </span><br />
<span class="Apple-style-span" style="font-family: Georgia, 'Times New Roman', serif; line-height: 18px;">Have a look at the <a href="http://content.onlinejacc.org/cgi/reprint/47/2/473.pdf?ijkey=89bad890d3675e090618cc7a44d8068f20b67430">American College of Cardiology recommendations</a> on evaluation of syncope.</span>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com1tag:blogger.com,1999:blog-809683702252526556.post-69767260927614901442010-12-28T21:03:00.000-05:002010-12-28T21:03:55.543-05:00FDA warnings in 2010!!<div style="color: black;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;"></span></span><br />
<div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">There has been quite a few warnings ... and threat from FDA about drugs...in 2010. </span></span><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://t3.gstatic.com/images?q=tbn:ANd9GcTFBtz2fdkemnEIZI3T3mutl_uK9cApWokqOWYhF01_0O0BZsS-" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="http://t3.gstatic.com/images?q=tbn:ANd9GcTFBtz2fdkemnEIZI3T3mutl_uK9cApWokqOWYhF01_0O0BZsS-" /></a></div><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;"><br />
</span></span><br />
<span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">The most popular news of the year among drug warnings was a repeat FDA warning that <i>off-label use of<span class="Apple-converted-space"> </span></i><a href="http://www.medscape.com/viewarticle/724798" style="color: black; text-decoration: none;" target="_blank"><i>quinine</i> for leg cramps</a><span class="Apple-converted-space" style="font-style: normal;"> </span>may result in serious and life-threatening hematologic adverse effects.</span></span></div><div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">Among other drug alerts, the FDA warned against taking<span class="Apple-converted-space"> </span></span></span></div><div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;"><span class="Apple-converted-space" style="font-style: normal;">* </span><span class="Apple-converted-space"><i><a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm">Long acting beta agonists</a> (LABA)</i></span><span class="Apple-converted-space" style="font-style: normal;"> </span>by themselves should not be taken for a long time by asthma patients, unless their symptoms are not controlled by other medications (like steroids)</span></span></div><div style="font-family: Arial, Verdana, Helvetica, sans-serif; margin-bottom: 5px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px;"><div style="text-align: left;"><span class="Apple-style-span" style="font-size: 13px;"><i>*80-mg dose of simvastatin</i> is associated with an increased risk for myopathy, including rhabdomyolysis </span></div></div><div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">*Opioid<span class="Apple-converted-space"><a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213264.htm"> tramadol</a></span><span class="Apple-converted-space"> </span>is linked to increased suicide risk</span></span></div><div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">*<a href="http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm">Bisphosphonates</a><span class="Apple-converted-space"> </span>used to treat osteoporosis have a possible increased risk for 2 types of atypical femur fractures(femoral subtrochanteric and femoral diapyseal fractures)...both of which account for <1% of all femoral/hip fractures overall.</span></span></div><div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;"><span class="Apple-converted-space">*<a href="http://medicineforresidents.blogspot.com/2010/08/rosiglitazone-is-it-curtains-down.html">Rosiglitazone(Avandia)</a></span><span class="Apple-converted-space"> </span>was allowed to remain available under a stringent restricted-access program, despite adverse cardiovascular effects<span class="Apple-converted-space"> </span></span></span></div><div style="font-family: Arial,Verdana,Helvetica,sans-serif; font-size: 12px; margin: 0px 0px 5px; padding: 0px;"><span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;"><span class="Apple-converted-space">* Tigecycline</span><span class="Apple-converted-space"> </span>was linked to an increased risk for death in patients with certain severe infections.(probably because its bacteriostatic)</span></span><br />
<span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">* A threat from FDA to withdraw <a href="http://medicineforresidents.blogspot.com/2010/09/midodrine-may-not-be-there.html">Midodrine</a> from the market....and a later "U" turn by FDA...allowing it to stay in the market (no idea what's happening!)</span></span><br />
<span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;"><br />
</span></span><br />
<span class="Apple-style-span" style="border-collapse: separate; font-family: 'Times New Roman'; font-size: small; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><span class="Apple-style-span" style="font-family: Arial, Verdana, Helvetica, sans-serif; font-size: 13px; text-align: left;">May be ARBs and cancer risk might be on the agenda for 2011!!</span></span></div></div>Samsonhttp://www.blogger.com/profile/13277946715205808465noreply@blogger.com4